Breast cancer and immunology: Biomarker and therapeutic developments

Cesar A. Santa-Maria, Sue Jung Park, Sarika Jain, William J. Gradishar

Research output: Contribution to journalReview article

Abstract

While breast cancer has not historically been considered an immunogenic cancer, recent data demonstrating the powerful anti-cancer effects of immune checkpoints in many cancers, including breast cancer, has reinvigorated the field. Although the responses are generally low with single agents, some patients experience disease control for a long period of time. Selecting appropriate patients for immunotherapy is an important area of research, and many biomarkers are under investigation. Although immunotherapies are still in their early stages of development, learning how to use them in combination with other agents that can alter antigen presentation or other immune elements will be crucial. This review aims to summarize efforts in immune-related biomarker and drug development, particularly as it pertains to breast cancer.

Original languageEnglish (US)
Pages (from-to)1215-1222
Number of pages8
JournalExpert Review of Anticancer Therapy
Volume15
Issue number10
DOIs
StatePublished - Oct 3 2015
Externally publishedYes

Keywords

  • biomarkers
  • breast cancer
  • checkpoint inhibitors
  • drug development
  • immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Breast cancer and immunology: Biomarker and therapeutic developments'. Together they form a unique fingerprint.

  • Cite this